ReviewJournal of clinical and experimental hepatology
Therapeutic Plasma Exchange in Hepatology: Indications, Techniques, and Practical Application.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The right patient, the right time: Revisiting plasma exchange in HAV-related acute liver failure.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Impact of extracorporeal circuits on systemic drug levels - a scoping review.Journal of anesthesia, analgesia and critical care · 2026Review
- Efficacy and safety analysis of double plasma molecular adsorption system plus plasma exchange for treating acute-on-chronic liver failure.American journal of translational research · 2026Article
- Low-Volume Plasma Exchange Combined With a Double Plasma Molecular Adsorption System is Superior to Standard-Volume Plasma Exchange in improving the MELD Score and Reducing Plasma Consumption in Adult Patients With Acute Liver Failure: A Multicenter Retrospective Cohort Study From Heilongjiang Province.Canadian journal of gastroenterology & hepatology · 2026Article
- Subacute liver failure caused by immunotherapy in a patient with gastric cancer was improved after multimodal treatment with artificial liver combined with liver-protective drugs: a case report.Frontiers in immunology · 2026Article
- Management of acute liver failure-an updated literature review.World journal of critical care medicine · 2025Review
- Machine learning-based algorithms for the prediction of 90-day survival in patients with liver failure receiving artificial liver therapy.Frontiers in physiology · 2025Article
- Clinical Utility of the Trajectory of Serum Bilirubin and International Normalized Ratio Values in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.International journal of general medicine · 2025Article
- Increasing incidence of mycotoxicosis in South-Eastern Germany: a comprehensive analysis of mushroom poisonings at a University Medical Center.BMC gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is sobering that many liver failure patients die in the absence of liver transplantation (LT), and reducing its morbidity and mortality urgently needs more non-transplant treatment options. Among the several artificial liver support devices available, therapeutic plasma exchange (TPE) is the only one that improves survival in acute liver failure (ALF) patients. In many other disorders, data on survival benefits and successful bridging to transplant is encouraging. TPE removes the entire plasma, including damage-associated-molecular patterns, and replaces it with healthy donor fresh frozen plasma. In contrast, other artificial liver support systems (ALSS) correct the blood composition through dialysis techniques. TPE has become increasingly popular due to advances in apheresis techniques and a better understanding of its applicability in treating liver failure's pathophysiology. It provides metabolicdetoxification, and synthetic functions and modulates early innate immunity, fulfilling the role of ALSS. TPE is readily available in intensive care units, dialysis units, or blood banks and has enormous potential to improve survival outcomes. Hepatologists must take advantage of this treatment option by thoroughly understanding its most frequent indications and its rationale and techniques. This primer on TPE for liver clinicians covers its current clinical, technical, and practical applications, addresses the knowledge gaps, and provides future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.